DRUG
Bright Minds Biosciences Inc. NASDAQ Listed Mar 22, 2021$76.53
+3.72%
vs $73.78
Mkt Cap $749.0M
52w Low $33.96
47.4% of range
52w High $123.75
50d MA $71.93
200d MA $75.71
P/E (TTM)
—
EV/EBITDA
—
P/B
6.4x
Debt/Equity
0.0x
ROE
—
P/FCF
-58.4x
RSI (14)
49.40
ATR (14)
$4.11
Beta
-0.11
50d MA
$71.93
200d MA
$75.71
Avg Volume
270.0K
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
1500 – 1055 West Georgia Street · New York City, BC V6E 4N7 · CA
Data updated apr 25, 2026 5:48am
· Source: financialmodelingprep.com